Catalyst ligands

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.787-70-2,[1,1′-Biphenyl]-4,4′-dicarboxylic acid,as a common compound, the synthetic route is as follows.

787-70-2, General procedure: A mixture of Eu(NO3)3¡¤6H2O (0.089 g,0.2 mmol), Na2L (0.112 g, 0.2 mmol), 1,10-phenanthroline¡¤H2O (0.04 g, 0.2 mmol), 4,4?-biphenyldicarboxylic acid (0.05 g, 0.2 mmol), one drop triethylamine and H2O(15.0 ml) in a 25 ml Teflon-lined autoclave was heated at 150 C for 33 h. After the mixture was cooled slowly to ambient temperature, yellow block crystals were obtained. The crystalswere filtered,washedwith distilledwater and dried at ambient temperature. The yield of the reaction,determined fromtheweight of the solvent-free material (0.138 g), is 71.5% based on Na2L. Anal. Calcd (%) for C47H32O8N2S2Eu: C,58.27; H, 3.33; N, 2.89. Found: C, 58.22; H, 3.42; N, 2.95. IR data (KBr pellet,upsilon/cm-1): 3062 (m), 3021 (m), 2668 (m), 2551 (m), 1685 (s), 1598 (s), 1417 (s),1252 (s), 760 (s), 607 (s). The procedure for preparing 2-4 is similar to that for 1,but the reaction temperature is 170 C rather than 150 C (see Supporting Information2).

787-70-2 [1,1′-Biphenyl]-4,4′-dicarboxylic acid 13084, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Shi, Dabin; Ren, Yanwei; Jiang, Huanfeng; Cai, Bowei; Lu, Jiaxian; Inorganic Chemistry Communications; vol. 24; (2012); p. 114 – 117,4;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

112881-51-3, 4′-(4-Pyridyl)-2,2′:6′,2”-terpyridine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A mixture of NiCl2¡¤6H2O (24mg, 0.10mmol) and pytpy (62mg, 0.20mmol) was dissolved in water (5mL) and then was stirred for 10min in air. The reaction mixture was then transferred into a 23mL Teflon-lined reactor and kept at 200C for 72h and after that it was cooled to room temperature at the rate of 10 Ch-1. The red crystals were obtained after washing with distilled water and drying in air. Yield: 74%; m.p. 344-346C (dec.). Anal. Calc. for C40H28Cl2N8Ni. 4H2O: C, 58.42; H, 4.41; N, 13.63. Found: C, 58.03; H, 4.08; N, 13.77. IR data (KBr, cm-1): 3404, 3015, 2916, 2849, 2352, 1670, 1603, 1537, 1469, 1402, 1249, 1159, 1016, 914, 793, 741, 634, 495. TGA: calc. by formula C40H28N8NiCl2. 1.5H2O: 1.5H2O %=3.48, 2 pyridine and 1 Cl %=25.89, 1Cl %=6.40, 0.5 pyridine %=7.62, 0.5 terpyridine and 0.5 pyridine %=32.57. determined: 1.5H2O %=3.37, 2 pyridine and 1 Cl %=27.18, 1 Cl %=5.35, 0.5 pyridine %=8.94, 0.5 terpyridine and 0.5 pyridine %=35.30.

112881-51-3, 112881-51-3 4′-(4-Pyridyl)-2,2′:6′,2”-terpyridine 11438308, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Momeni, Badri Z.; Rahimi, Farzaneh; Jebraeil, S. Mohammad; Janczak, Jan; Journal of Molecular Structure; vol. 1150; (2017); p. 196 – 205;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

137076-54-1, 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

(1) To a solution of tri-tert-butyl 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate (24.8 mg) in DMF (0.2 mL) and DIEA (17 muL), a solution of HBTU (17.0 mg) in DMF (100 muL) was added, then the mixture was added to a solution of compound (L7) (13.1 mg) in DMF (200 muL) and DIEA (10 muL), and the resulting mixture was stirred at room temperature for 1 hour. Water (200 muL) was added thereto, and the mixture was purified by preparative HPLC to obtain compound (M1) (12.3 mg). LC/MS (SunFire) rt (min): 11.05 MS (ESI, m/z): 730.95 [M+2H]2+, 1459.05 [M-H]-

137076-54-1, The synthetic route of 137076-54-1 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; FUJIFILM Corporation; FUJIFILM RI PHARMA CO., LTD.; FUKUNAGA, Hirofumi; DOZONO, Hiroyuki; HINO, Akihiro; OSHIKIRI, Shinobu; NAGANO, Akio; (99 pag.)US2016/199520; (2016); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.144222-34-4,N-((1R,2R)-2-Amino-1,2-diphenylethyl)-4-methylbenzenesulfonamide,as a common compound, the synthetic route is as follows.

Step 5: Preparation of catalyst 14; The catalyst was prepared by mixing lmol equiv of [RuCl2(p-cymene)2], 2mol equiv(R,R)-N-Tosyl-l,2-diphenylethylene-l,2-diamine and 4.2 mol equiv OfEt3N in iPrOH at 80 0C for Ih. After solvent removal, the solid was washed with cold H2O and the recrystallized from MeOH to give the catalyst as an orange solid., 144222-34-4

144222-34-4 N-((1R,2R)-2-Amino-1,2-diphenylethyl)-4-methylbenzenesulfonamide 2734565, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; MERCK FROSST CANADA LTD.; WO2007/14454; (2007); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.4733-39-5,2,9-Dimethyl-4,7-diphenyl-1,10-phenanthroline,as a common compound, the synthetic route is as follows.,4733-39-5

(1) Synthesis of 2,9-bis(tosylaminomethyl)-4,7-diphenyl-1,10-phenanthroline (x) 2,9-Bis(aminomethyl)-4,7-diphenyl-1,10-phenanthroline perchlorate (w) (2.36 g, 4 mmol), which was synthesised from 2,9-dimethyl-4,7-diphenyl-1,10-phenanthroline according to the method described in J. Heterocyclic Chem., 18, 599 (1981), was dissolved in pyridine (20 ml). p-Toluene sulfonyl chloride (1.6 g, 8 mmol) was added to the solution with cooling using an ice bath, and the reaction mixture was stirred at room temperature for 3 hours. The resulting solution was poured into water (200 ml) and extracted with chloroform (200 ml). The chloroform layer was chromatographed on a silica gel column using chloroform/methanol as eluent to give the desired 2,9-bis(tosylaminomethyl)-4,7-diphenyl-1,10-phenanthroline (x) (yield=1.54 g).

4733-39-5 2,9-Dimethyl-4,7-diphenyl-1,10-phenanthroline 65149, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Dojindo Laboratories; Mochida Pharmaceutical Co., Ltd.; US5262526; (1993); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

162318-34-5, 5-Ethynyl-2,2′-bipyridine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

For the cross-coupling reaction leading to 5-ethynyl-2,2?-bipyridine (0.150 g, 0.83 mmol), the 5-bromo-2,2?-bipyridine (0.200 g, 0.83 mmol) was dissolved in benzene at 80 C. When a clear solution was obtained, [Pd(PPh3)4] (0.092 g, 0.08 mmol) and 5 mL of triethylamine were added. After 24 h of heating at 80 C, the solvent was removed under vacuum and the residue was purified by flash column chromatography (silica gel, MeOH/CH2Cl2 = 1/9). Yield: 48% (133 mg), TLC (SiO2): Rf 0.28 (10% methanol/dichloromethane); IR (KBr, cm-1) 3053 (Ar-H), 3008 (Ar-H), 2923 (Ar-H), 2850 (Ar-H), 1456 (aromatic C=C), 798 (Ar-C), 1H NMR (400 MHz, CDCl3) delta 7.32-7.35 (m, 2H, PyH), 7.82-7.86 (m, 2H, PyH), 7.97-8.00 (m, 2H, PyH), 8.43-8.46 (m, 4H, PyH), 8.70-8.71 (m, 2H, PyH), 8.85-8.86 (m, 2H, PyH); HRMS: m/z calc. for C22H14N4: calc. for 336.1375, found 336.1369., 162318-34-5

The synthetic route of 162318-34-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Kim, Minki; Kang, Chang Hoon; Hong, Subong; Lee, Won-Yong; Kim, Byeong Hyo; Inorganica Chimica Acta; vol. 395; (2013); p. 145 – 150;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.3779-42-8,3-Bromo-N,N,N-trimethylpropan-1-aminium bromide,as a common compound, the synthetic route is as follows.

Compound 30 (100 mg, 0.12 mmol) is dissolved and K2CO3 (230 mg, 1.7 mmol) is suspended in DMF (30 mL). To the vigorously-stirred mixture a solution of (1-BROMOPROPYL)-TRIMETHYLAMMONIUM bromide (0.3 g, 16.6 mmol) in DMF (10 mL) is added dropwise at 50C during 30 mins and the mixture is heated for 18 h. After removal of DMF under reduced pressure, the residue obtained is dissolved in methanol (5 mL) and filtered through a pad of silica gel (depth 2 CM) supported on a steel frit (diameter 3.5 CM). After washing the pad with methanol (ca. 500 mL) it is eluted with acetic acid: methanol: water (3: 2: 1, by vol. ). After evaporation of solvent from appropriate combined fractions under reduced pressure, the residue is purified by chromatography on a column (2.5 x 40 CM) of Sephadex LH-20 eluting with n-butanol: water: acetic acid (5: 4: 1, by vol. , upper phase). After removal of solvent under reduced pressure from the eluate, the residue obtained is dissolved in methanol and the solution is passed through a short column (3.5 x 20 cm) of anion exchange resin (Amberlite IRA 400, chloride form). Evaporation of solvent from the eluate gives the product which is dried under high vacuum. 1H-NMR : aH (300MHZ, CD30D) : 0.75-0. 80 (m, 3 H), 1.00-1. 40 (m, 18 H), 1.60- 1.80 (bs, 2 H), 2.25-2. 40 (bs, 6 H), 3.29 (bs, 27 H), 3.40-3. 60 (m, 6 H), 3.90-4. 00 (m, 2 H), 4.05-4. 25 (m, 6 H), 7.10-7. 20,7. 25-7.40, 7.60-7. 80, 7.80-7. 90 (4 x m, 16H), 8.70-9. 00 (bs, 8 H)., 3779-42-8

The synthetic route of 3779-42-8 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; DESTINY PHARMA LIMITED; SOLVIAS AG; WO2004/56828; (2004); A2;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

485-71-2, Cinchonidine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: The phase-transfer catalysts (C1-C11) were synthesized according to the proceduresbelow. To a solution of cinchonidine (1.00 g, 3.4 mmol) in THF (50 mL) was addedthe aryl benzyl bromides (3.4 mmol). The mixture was heated for 6-8 h at reflux.After cooling to room temperature, the mixture was poured into MTBE (150 mL)under stirring. The precipitated solid was filtrated and recrystallized fromCH3OH/MTBE to afford C1-C11

485-71-2, As the paragraph descriping shows that 485-71-2 is playing an increasingly important role.

Reference£º
Article; Li, Ruipeng; Liu, Zhenren; Chen, Liang; Pan, Jing; Zhou, Weicheng; Beilstein Journal of Organic Chemistry; vol. 14; (2018); p. 1421 – 1427;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

62937-45-5,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.62937-45-5,D-Prolinamide,as a common compound, the synthetic route is as follows.

A solution of N(4-(5-(difluoromethyl)- 1,3 ,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide(0.100 g, 0.255 mmol), D-(-)-prolinamide (0.058 g, 0.5 11 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stilTed at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (Waters, Cl 8; acetonitrile / aqueous 0.1%-formic acid solution = 10 % to 90 %) to give (R)- 1 -(2-(N-(4-(5-(difluoromethyl)- 1,3 ,4-oxadiazol-2-yl)benzyl)-N-phenylsulfamoyl)e thyl)pyffolidine-2-carboxamide as white solid (0.120 g, 92.9 %).?H NMR (400 MHz, DMSO-d6) oe 7.96( d, 2 H,J = 8.4 Hz), 7.50 (d, 2 H, J = 8.3 Hz), 7.43 -7.22 (m, 6 H), 7.11 (br, 2 H), 5.00 (s, 2 H), 4.02 (q, 1 H, J= 5.2 Hz), 3.47 (m, 2 H), 3.32 (s, 1 H), 3.15 – 3.13 (m, 1 H), 2.94 – 2.81 (m, 2 H), 2.34 – 2.30 (m, 1 H), 2.06 (m, 1 H), 1.74 – 1.69 (m, 2 H); LRMS (ES) mlz 506.1 (M+1).

As the paragraph descriping shows that 62937-45-5 is playing an increasingly important role.

Reference£º
Patent; CHONG KUN DANG PHARMACEUTICAL CORP.; LEE, Jaekwang; HAN, Younghue; KIM, Yuntae; CHOI, Daekyu; MIN, Jaeki; BAE, Miseon; YANG, Hyunmo; KIM, Dohoon; (644 pag.)WO2017/18803; (2017); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.5350-41-4,N,N,N-Trimethyl-1-phenylmethanaminium bromide,as a common compound, the synthetic route is as follows.

5350-41-4, [Method A (cations)] Titrationcurves were obtained in CDCl3 at 25 oC, by adding stocksolution of host 1 to a constantconcentration (2 mM) of a guest. Up-field shift of the guest cation, especiallyCH3 or CH2, was observed. Plots of the variations of thechemical shift of the guest upon addition of the titration were registered.[Method B (anions)] Similarly,titration curves were obtained in CDCl3 at 25 oC, byadding stock solution of a guest to a constant concentration (2 mM) of host 1. Since down-field shift of amideprotons of the host 1 was observed,plots of the variations of the chemical shift of the guest upon addition of thetitration were registered.[Estimation of Ka]Titration data were then treated according to a standard binding isotherm forthe case of 1:1 association.2 Non-linear curve fitting usingKaleidaGraph 4.1 (Synergy Software) software package afforded Ka and Ddmax.

5350-41-4 N,N,N-Trimethyl-1-phenylmethanaminium bromide 21449, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Akazome, Motohiro; Hamada, Norihiro; Takagi, Koji; Yagyu, Daisuke; Matsumoto, Shoji; Tetrahedron Letters; vol. 55; 14; (2014); p. 2226 – 2229;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI